EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in KRASG12D-targeted therapy: from small-molecule inhibitors to PROTACs and molecular glues

Sichang Hao, Tianjiao Niu, Xinrong Wu, Chongqiang Mu, Mengxue Wang, Huimin Liu, Haibin Lu

Bioorganic Chemistry · 2026-11 · 183 · 110633

DOI: 10.1016/j.bioorg.2026.110633 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2026-11. Verfasst von Sichang Hao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jilin University School of Pharmaceutical Sciences, Changchun 130021, Jilin Province, China. Hauptthemen laut MEDLINE: Small Molecule Libraries, Antineoplastic Agents, Proto-Oncogene Proteins p21(ras), Neoplasms. Die Arbeit nennt 80 Literaturangaben. Gefördert von: Jilin Scientific and Technological Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS gene mutations represent one of the most common drivers of human cancers, with particularly high prevalence in pancreatic, lung, and colorectal cancers. Among these, the KRASG12D mutation has long been considered an "undruggable" target because of its unique structural characteristics. This article systematically reviews the biological characteristics and oncogenic mechanisms of the KRASG12D mutation. It highlights its key roles in metabolic reprogramming and shaping the tumor immune microenvironment. The mechanisms by which KRASG12D promotes tumor initiation and progression through activation of downstream signaling pathways such as MAPK/ERK, PI3K/AKT/mTOR, and Ral-GDS are also discussed. The review focuses on various emerging therapeutic strategies targeting KRASG12D. It provides a detailed overview of research advances in small-molecule inhibitors, PROTAC-based approaches, and molecular glue therapies. Finally, the current challenges and opportunities in KRAS inhibitor research are discussed, with the aim of offering new perspectives and strategies for future KRAS-targeted drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Molecule LibrariesAntineoplastic AgentsProto-Oncogene Proteins p21(ras)NeoplasmsMolecular Targeted TherapyHumansProteolysis Targeting ChimeraMolecular StructureMutation

Stichwörter der Autor:innen

KRAS(G12D) mutationMolecular gluesOncogenic mechanismsPROTACSmall-molecule inhibitors

Substanzen

Small Molecule LibrariesProteolysis Targeting ChimeraAntineoplastic AgentsProto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Jilin University School of Pharmaceutical Sciences, Changchun 130021, Jilin Province, China.
  • Jilin University School of Pharmaceutical Sciences, Changchun 130021, Jilin Province, China. Electronic address: luhaibin@jlu.edu.cn.

Förderung

  • Jilin Scientific and Technological Development Program

Zitieren

APA

Hao, S., Niu, T., Wu, X., Mu, C., Wang, M., Liu, H., & Lu, H. (2026). Advances in KRASG12D-targeted therapy: from small-molecule inhibitors to PROTACs and molecular glues. Bioorganic Chemistry, 183, 110633. https://doi.org/10.1016/j.bioorg.2026.110633

Vancouver

Hao S, Niu T, Wu X, Mu C, Wang M, Liu H, et al. Advances in KRASG12D-targeted therapy: from small-molecule inhibitors to PROTACs and molecular glues. Bioorganic Chemistry. 2026;183:110633. doi:10.1016/j.bioorg.2026.110633

BibTeX
@article{Hao2026,
  author = {Hao, Sichang and Niu, Tianjiao and Wu, Xinrong and Mu, Chongqiang and Wang, Mengxue and Liu, Huimin and Lu, Haibin},
  title = {Advances in KRASG12D-targeted therapy: from small-molecule inhibitors to PROTACs and molecular glues},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {183},
  pages = {110633},
  doi = {10.1016/j.bioorg.2026.110633}
}
Kostenlos starten →